BeyondBio’s BEY2153 Targets Beta-Amyloid and Tau Simultaneously
BeyondBio’s BEY2153 Targets Beta-Amyloid and Tau Simultaneously
  • Hyun Duk Yang
  • 승인 2021.11.20 09:10
  • 댓글 0
이 기사를 공유합니다

Pending phase 1 result
$13.4 million capital increase
BeyondBio
BeyondBio

After repeated disappointments with amyloid-targeting agents in Alzheimer’s disease (AD), attention in AD research has in part turned to tau. Moreover, efforts are being made to target amyloid and tau at the same time for the treatment of AD.

BeyondBio, headquartered in Daejeon, a Korean biopharmaceutical company, is developing an innovative investigational drug (named BEY2153) that inhibits the aggregation of beta-amyloid and tau simultaneously. 

The preclinical studies with AD animal models demonstrated that BY2153 inhibited neuronal death while enhancing cognitive and behavioral functions. BY2153 started its phase 1 study in August 2020 which was supposed to be completed in October 2021.

Meanwhile, in September BeyondBio carried out a paid-in capital increase worth $13.4 million which will fuel the further research and development. In parallel with this, BeyondBio is preparing for the KOSDAQ (Korea Securities Dealers Automated Quotation) listing through the ‘Special Technology Assessments Track’. Previously, BeyondBio had applied for the Technology Evaluation in 2019 but in vain.

 

Phase 1 Clinical Trial (NCT04476303)

A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants



댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.